KemPharm Inc. (NASDAQ:KMPH)’s share price traded up 2.8% during trading on Thursday . The company traded as high as $4.55 and last traded at $4.44, with a volume of 56,591 shares traded. The stock had previously closed at $4.32.

KMPH has been the topic of a number of recent research reports. Canaccord Genuity reiterated a “buy” rating on shares of KemPharm in a research note on Saturday, May 14th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of KemPharm in a research note on Saturday, May 14th. Royal Bank Of Canada reiterated a “buy” rating on shares of KemPharm in a research note on Sunday, May 8th. Finally, Zacks Investment Research upgraded KemPharm from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research note on Tuesday, August 16th.

The stock’s 50 day moving average price is $4.40 and its 200-day moving average price is $9.52. The company’s market cap is $67.96 million.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.36. On average, equities analysts anticipate that KemPharm Inc. will post ($1.72) EPS for the current fiscal year.

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.